Compartment-model based quantification of beta-amyloid binding with Florbetaben PET inAlzheimer'sdisease and control subjects

Objectives: Florbetaben is a promising PET tracer for imaging of β-amyloid deposits in human brains. This F-labeled stilbene derivative is rapidly metabolized in vivo, producing low molecular weight, polar metabolite(s), which appear to enter the brain. We aimed to model the presence of the polar metabolite(s) in the brain in the quantification of β-amyloid binding from Florbetaben human PET data of Alzheimer's disease (AD) and healthy control (HC) subjects.